A quality-by-design strategic approach for the development of bedaquiline-pretomanid nanoparticles as inhalable dry powders for TB treatment-Reference-Cited by-同舟云学术

A quality-by-design strategic approach for the development of bedaquiline-pretomanid nanoparticles as inhalable dry powders for TB treatment

Published:2024-03 Issue: Volume:653 Page:123920
ISSN:0378-5173
Container-title:International Journal of Pharmaceutics
language:en
Short-container-title:International Journal of Pharmaceutics

Author:

Patil Suyash M.^ORCID,Diorio Alec M.^ORCID,Kommarajula Parasharamulu,Kunda Nitesh K.^ORCID

Publisher

Elsevier BV

Reference87 articles.

1. Alginate modified-PLGA nanoparticles entrapping amikacin and moxifloxacin as a novel host-directed therapy for multidrug-resistant tuberculosis;Abdelghany;J. Drug Deliv. Sci. Technol.,2019

2. Evolution of drug-resistant mycobacterium tuberculosis strains and their adaptation to the human lung environment;Allué-Guardia;Front. Microbiol.,2021

3. Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties;Ambrus;Eur. J. Pharm. Sci.,2018

4. Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis;Andreu;Nanomed.,2019

5. Mesoporous silica nanoparticles improve oral delivery of antitubercular bicyclic nitroimidazoles;Ang;ACS Biomater. Sci. Eng.,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality by Design in Pulmonary Drug Delivery: A Review on Dry Powder Inhaler Development, Nanotherapy Approaches, and Regulatory Considerations;AAPS PharmSciTech;2024-08-02

2. Design of Experiment (DoE) Approach for Developing Inhalable PLGA Microparticles Loaded with Clofazimine for Tuberculosis Treatment;Pharmaceuticals;2024-06-07